Kornimate/medical-research-clean huggingface dataset:
measurement of retinal blood flow, retinal oxygenation and retinal oxygen extraction in healthy subjects during normoxia and systemic hyperoxia

Conditions: Healthy; Normoxia; Systemic Hypoxia

Summary: the inner retina is crucially dependent on an adequate retinal blood supply. when the retina becomes ischemic and hypoxic this results in severe vision loss due to retinal neovascularization. measurement of retinal blood flow and retinal oxygenation is, however, still a difficult task. information on retinal oxygenation is almost unavailable from human studies. in the present protocol the investigators propose a procedure allowing for the measurement of retinal blood flow, retinal oxygenation and retinal oxygen extraction by combining a number of innovative techniques. specifically, retinal vessel diameters will be measured with a retinal vessel analyzer, retinal blood velocities with bi-directional laser doppler velocimetry and retinal oxygenation with spectroscopic evaluation of retinal fundus images. this will allow for the calculation of retinal oxygen extraction, a fundamental parameter of retinal function. up to now, no data for retinal oxygen extraction are available in the literature.


Eligibility criteria:
inclusion criteria: * men and women aged between 18 and 35 years * nonsmokers * body mass index between 15th and 85th percentile * normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant * normal laboratory values unless the investigator considers an abnormality to be clinically irrelevant * normal ophthalmic findings, ametropia \< 3 dpt exclusion criteria: * regular use of medication, abuse of alcoholic beverages, participation in a clinical trial in the 3 weeks preceding the study * treatment in the previous 3 weeks with any drug except oral contraceptives * symptoms of a clinically relevant illness in the 3 weeks before the first study day * blood donation during the previous 3 weeks * pregnancy

Keywords: ocular physiology
effect of intensified occupational therapy on basic activities of daily living

Conditions: ADL

Summary: the objective is to investigate the effect of an intensified occupational therapy intervention on independence in basic activities of daily living (adl) in subjects with stroke


Eligibility criteria:
inclusion criteria: * first-time stroke * \<=4 on four of six functional independence measure (fim) basic adl items exclusion criteria: * not able to understand danish

Keywords: stroke occupational therapy trial basic activities of daily living
in-use test of a cosmetic product in subjects with chronically itchy scalp

Conditions: Pruritus of the Scalp

Summary: the aim of the study is to evaluate the tolerance of the shampoo (wo 5101) on the scalp by a dermatologist and by the subjects themselves after four weeks of regular product use. additional objective of this clinical in-use study was to evaluate the cosmetic features and the acceptance of the product by means of a questionnaire at the end of the 4-week treatment period.


Eligibility criteria:
inclusion criteria: * age: ≥ 18 years * with chronically itchy scalp * normal to dry scalp or scalp prone to neurodermatitis exclusion criteria: * any deviation from the above-mentioned criteria * users of sour hair conditioner * subjects who wash their hair more than once a day * other dermatological disorders (scars, moles) on the scalp * known incompatibilities to cosmetics and ingredients of cosmetic test products (please see inci) * topical medication in the test area within 1 month prior to study start * systemic medication with anti-inflammatory agents and antibiotics within two weeks prior to starting of the study * systemic medication with retinoids, antihistamines and/or immunomodulators (e.g. cortisone, corticosterone, chemotherapeutic agents) within four weeks prior to starting of the study * severe internistic disease that leads to pruritus

Keywords: itchy scalp chronic pruritus
improving cancer family caregivers' knowledge and communication about care options

Conditions: Family Caregivers

Summary: the purpose of this two-year mixed methods study is to develop and test an intervention to improve cancer family caregivers' knowledge of care options (curative, palliative, and hospice care) and goals of care communication as part of a self-management (sm) training program. the two specific aims of this project are to: 1. develop a psycho-educational intervention called managing cancer care: a caregiver's guide (mcc-cg), for family caregivers of patients with breast cancer to increase knowledge of care options, goals of care communication, and other sm skills. 2. evaluate the feasibility and preliminary efficacy of the mcc-cg in a pilot randomized controlled trial compared with an attention-control condition (symptom management education) on knowledge of care options, goals of care communication, and other key sm skills (engagement in sm, management of transitions and uncertainty, increasing self-efficacy, appropriate use of health care resources).

the investigators will address and accomplish aim 1 by taking the following steps: 1. conduct development focus groups with family caregivers of women with breast cancer. 2. develop the mcc-cg intervention prototype. 3. conduct feedback focus groups with family caregivers to evaluate the prototype. 4. revise the mcc-cg. to address and accomplish aim 2, the investigators will do the following: 1. conduct a pilot rct to evaluate the feasibility of recruiting and retaining a sample of family caregivers. 2. assess the initial efficacy of the mcc-cg to improve knowledge of care options, goals of care communication, and other sm skills. 3. estimate power and determine the best measures for a large rct testing the mcc-pt and mcc-cg together.

Eligibility criteria:
inclusion criteria: * a family member of an individual with any stage of breast cancer receiving curative, palliative, or hospice care * aged 18+ * english speaking * live in connecticut * the patient for whom the participant is a caregiver has a six-month prognosis

Keywords: caregiver self-management care options goals of care breast cancer palliative care
clinical trials for elderly patients with multiple disease

Conditions: Chronic Obstructive Pulmonary Disease (COPD); Congestive Heart Failure (CHF); Sleep Disordered Breathing (SDB)

Summary: the chromed project focuses its investigation on the applicability of an integrated solution for a pathological condition which: a) is very prevalent in ageing patients and b) severely impairs quality of life: copd with other typical comorbidities such as congestive heart failure and sleep disordered breathing. a specific ict platform in combination with a set of innovative devices will be used to collect and process useful clinical data at the patient's home and used to optimize their medical treatment. to evaluate the impact of this solution, an international multi-centric randomized control trial will be implemented in five european regions: united kingdom, sweden, estonia, spain and slovenia, representing different social and organizational contexts in europe.


Eligibility criteria:
inclusion criteria: * copd gold grade ii or higher with a prior history of exacerbations and/or an hospitalization for copd in the previous year with one or more documented non-pulmonary chronic conditions such as: * chf due to left ventricular systolic dysfunction (lvsd) confirmed on echocardiography * sdb identified by respiratory sleeping studies or polysomnography * current or prior smoking history of \>= 10 pack/years * subjects capable of providing signed written informed consent * subjects capable of perform study procedures and use the resmonpro at home * subjects with reliable mobile phone coverage at home exclusion criteria: * any disease that, in the opinion of the investigator, put the subject at risk * subjects with significant vision disturbance and mental diseases * subjects with a planned prolonged absence from home

Keywords: copd chf sdb
completion and acceptability of treatment across primary care and the community for latent tuberculosis

Conditions: Latent Tuberculosis

Summary: this study investigates whether recent migrants to the united kingdom are more likely to complete treatment for latent tuberculosis infection (ltbi) if they are treated in the community (by general practitioners/family doctors and pharmacists) than in a hospital tb clinic.

people with dormant/latent tb (ltbi) have tb bacteria in their bodies, but do not have any symptoms because the bacteria are not active. the investigators know that recent migrants with ltbi from countries where tb is very common (incidence greater than 150 per 100 000) are at risk of developing active tb (their dormant bacteria become active) after they arrive in the uk. active tb can be both infectious and deadly. the treatment for ltbi is three-month course of antibiotics. this significantly reduces the risk of developing active tb. this treatment is currently arranged and supervised by hospital clinics, however, many migrants do not attend and numbers of people completing antibiotics is low. this leaves many at risk of developing active tb. this study investigates whether a community (primary care) based approach to the treatment of ltbi, coordinated by general practices and local pharmacists, will achieve higher rates of antibiotic completion. the london borough of newham, in the uk, has amongst the highest rates of active tb in western europe. as part of a strategy to tackle this disease burden, an innovative model of care has been implemented in the borough in which gps and pharmacists screen and treat migrants with ltbi. our trial will evaluate whether primary care based management of ltbi leads to higher rates of treatment completion amongst recent migrants when compared to hospital based care. this approach would save money (both for the health service and for patients in terms of travels costs) and reduce numbers of new cases of active tb. the treatment for latent tuberculosis infection will be 3 months of combined oral rifampicin and isoniazid with pyridoxine. the dosage is weight dependent.

Eligibility criteria:
inclusion criteria: * patients with ltbi aged 16-35 and who have entered the uk less than 5 years ago from a country with a tb incidence of greater than 150/100,000. * latent tuberculosis is defined as a positive igra test without any symptoms or physical signs of active tuberculosis and no evidence of active tuberculosis on chest x-ray. exclusion criteria: 1. pregnant or breastfeeding women 2. patients requiring medications that cannot be safely taken with rifinah 3. hiv infection. 4. individuals with known liver disease, or abnormal liver function tests (lfts) 5. diagnosis of cirrhosis (jaundice, haematemesis, ascites or previous episodes of liver encephalopathy) 6. chronic or active hepatitis b or hepatitis c virus infection 7. previous treatment for tb or ltbi. 8. individuals who are unable to consent or who would usually be offered ltbi treatment under dot because of their mental or social disabilities or those with drug or alcohol abuse 9. evidence of active tb
a multi-center investigation of patient acceptability of opti-free replenish® multi-purpose disinfecting solution (mpds)

Conditions: Myopia

Summary: the purpose of this study was to demonstrate that current successful fulltime daily wear soft contact lens wearers using competitive multi-purpose solutions will note improved comfort when using opti-free replenish®.


Eligibility criteria:
inclusion criteria: 1. participants must be between 18 and 65 years of age. 2. must wear daily wear soft contact lenses a minimum of 8 hours per day,7 days a week. 3. must be wearing a planned replacement soft lens in a 2 week or monthly replacement modality. 4. must be using either complete multi-purpose solution (mps) easy rub or renu multiplus brand solution for at least 30 continuous days prior to enrollment. 5. must be free of any contact lens-related symptoms with regard to comfort and vision throughout their wearing hours prior to enrollment, with the exception of end-of-day dryness not limiting all day wear. 6. must have best corrected distance visual acuity, with contact lenses, of 20/30 or better in each eye. 7. must be willing to maintain pre-enrollment systemic medication regimens during the study. 8. must be willing to not use any topical medications or rewetting drops during the 30 day clinical trial duration. 9. other protocol-defined inclusion criteria may apply. exclusion criteria: 1. has used any topical medication or rewetting drops for 7 days prior to enrollment. 2. achieves best visual correction by monovision. 3. has modified their systemic medications within 30 days prior to enrollment. 4. has switched brands of cosmetics during the 30 days prior to the study. 5. has a history of allergy to any study product ingredients. 6. is unwilling or unable to meet the study visit timeline. 7. has any active corneal, eyelid or other anterior segment inflammation or infection, which, in the opinion of the investigator, would adversely affect successful contact lens wear. 8. other protocol-defined exclusion criteria may apply.

Keywords: contact lens solution opti-free replenish contact lenses
role of iv calcium to prevent diltiazem-related hypotension

Conditions: Atrial Fibrillation; Rapid Ventricular Response; Hypotension Drug-Induced

Summary: the objective of this study is to examine the efficacy and safety of iv calcium pretreatment at varying doses prior to weight-adjusted iv diltiazem on the incidence of diltiazem-related hypotension in adult patients presenting to the emergency department due to atrial fibrillation with rapid ventricular response. specifically, we tested the hypothesis that patients with atrial fibrillation who receive iv calcium pretreatment prior to iv diltiazem suffer less hypotension than those receiving diltiazem monotherapy.

patients were randomly divided into one of three groups. we assessed the systolic blood pressure and heart rate of participants before treatment and 5, 10, and 15 min after treatment among the patient groups. successful rhythm control was defined as achieving an hr of \&lt;100 bpm, a reduction in hr by \&gt;20% compared to baseline, or the restoration of normal sinus rhythm (nsr). if adequate rhythm control was not achieved within 15 min of the initial treatment, we administered 0.35 mg/kg of iv diltiazem slowly over 2 minutes as a rescue treatment. the need for rescue treatment or any intervention for hypotension, as well as any adverse effects, were recorded in a prepared data form. also, patient demographics (age and sex), new onset versus chronic afib/afl, relevant medical history, vital signs on admission (sbp and hr), complaints and symptoms on admission, and laboratory parameters were documented in a prepared data form.

Eligibility criteria:
inclusion criteria: * patients aged ≥ 18 years * patients with documented afib/afl (confirmed by ecg) * patients with a heart rate of ≥ 120 bpm, and a systolic blood pressure of ≥ 90 mmhg exclusion criteria: * patients under 18 years of age * pregnant individuals * patients with hemodynamic instability requiring electrocardioversion * patients with a documented history of sick sinus syndrome, third-degree av block, wolff-parkinson-white syndrome * patients with hypotension (sbp \&lt;90 mmhg) * patients with known or suspected hypercalcemia * patients with a confirmed allergy to diltiazem * patients with concurrent use of another heart rate control agent (such as beta-blockers, amiodarone, or digoxin) on the same admission

Keywords: atrial fibrillation rapid ventricular response diltiazem-related hypotension iv calcium
diagnostic performance of antenatal ultrasound in the localization of intestinal structures involved in malrotation with a higher-risk of volvulus

Conditions: Pregnancy Related

Summary: the aims of this study are: * to assess the performance of third-trimester ultrasound scan in the localization of intestinal structures (small bowel, gut, mesenteric vessels..) involved in malrotations with a higher-risk of volvulus compared to a gold standard based on fetal mri. * to describe normal meconium progression (ultrasound and mri), prenatal anatomical variants of the fetal digestive tract, and interobserver agreement on prenatal ultrasound.


Eligibility criteria:
inclusion criteria: * pregnant women over the age of 18 * good understanding of french * gestational age greater than or equal than 31 weeks * fetal mri indication validated in multidisciplinary staff at weekly meetings of the multidisciplinary prenatal diagnosis center in montpellier or nimes * affiliation or beneficiary of a social security scheme * declaration of free and enlightened opposition exclusion criteria: * complex fetal abdominal malformations responsible for difficult interpretation of imaging: heterotaxis with asplenia or polysplenium, diaphragmatic hernia, omphalocele, gastroschisis, digestive pathology, abdominal tumor, bladder exstrophy or megavessia. * fetal chromosomal abnormality * request for termination of pregnancy validated by a multidisciplinary pre-natal diagnosis center

Keywords: malrotation intestinal structures mesenteric vessels
study evaluating prevenar vaccine in healthy infants

Conditions: Pneumococcal Infections

Summary: to determine the immunogenicity of prevenar in infants immunized at 2, 4 and 6 months of age. to determine the antibody responses to the seven pneumococcal vaccine serotypes one month after second dose and determine the safety of prevenar in infants immunized at 2,4 and 6 months of age.


Eligibility criteria:
inclusion criteria: * healthy male and female children 2 months of age (42 to 100 days) in good health. * an informed consent must be signed by a parent or legal guardian following a detailed explanation of participation in the study. * infants whose parent(s)/guardian(s) will be available for the entire study period. exclusion criteria: * hypersensitivity to any component of the vaccine, including diphtheria toxoid * infants with thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection * infants with known or suspected impairment of immunologic functions including hiv or those receiving immunosuppressive therapy. other exclusions apply.

Keywords: vaccine healthy infants
botulinum a toxin in the treatment of patients with painful bladder syndrome

Conditions: Painful Bladder Syndrome (PBS)

Summary: previous clinical observations showed that botulinum a toxin (bont/a) has also an antinociceptive effect and can control the neuropathic pain. in the urologic field, recent in in vitro and in in vivo studies demonstrated that the neurotoxin is able to inhibit the release of several neurotransmitters from the bladder afferent fibers and urothelium. these neurotrasmitters as sp, cgrp, atp, ngf and prostaglandins are involved in neurogenic inflammation. thus, it is reasonable to hypothesize that patients with affected by painful bladder syndrome (pbs) could benefit from bont/a intravesically administered. the aim of the study is to investigate the clinical and urodynamic effects of an intravesical treatment with bont/a in patients affected by pbs associated with increased urinary frequency, who are refractory to conventional treatments. this treatment will be compared to bladder over distention, which is considered a conventional therapy.

patients with refractory pbs will be prospectively enrolled in the study. baseline evaluation: clinical evaluation with visual analog scale (vas) for pain quantification; qol assessment with a standardized questionnaire, ham-a and ham-d scales for the evaluation of anxiety and depression; voiding diary with the recording of diurnal and nocturnal urinary frequency; urodynamic evaluation, 1 month before commencing the study. treatment: according to a computerized randomization, patients will receive: a) one single injection of bont/a, 100 u diluted in 10 ml normal saline into the bladder, under cystoscopic guidance, under local anesthesia ; or b) one single bladder overdistension under local anesthesia. c) one single injection of placebo (nacl 0.9 % 10 ml) under local anesthesia. follow up: clinical evaluation (vas, ham-a and ham-d, qol assessment, voiding diary) and urodynamics three months after treatment.

Eligibility criteria:
inclusion criteria: * refractory bladder pain, the urgency-frequency syndrome, and sterile urine exclusion criteria: * neurological diseases * pregnancy and concomitant use of aminoglycosides and anticoagulants

Keywords: botulinum a toxin painful bladder syndrome (pbs) bladder overdistention
comparison of conservative treatment and graston and cup applications in patients with cervical disc herniation

Conditions: Neck Pain; Cervical Disc Herniation

Summary: the aim of the study is to examine the effects of graston and dry cupping techniques applied in addition to the conservative treatment program on neck awareness, grip strength, balance and sleep quality in patients with cervical disc herniation between the ages of 18-65.

the research will be carried out on 30 cases diagnosed with cervical disc herniation between the ages of 18-65. the patients will be divided into 2 groups as control and experimental groups by simple randomization method. while the conservative physical therapy program is applied to the control group, the patients in the experimental group will be applied 1 day graston and 1 day dry cup technique in addition to the ones in the experimental group. all patients will be treated for 20 sessions, 5 days / 4 weeks. fremantle neck awareness questionnaire to assess neck awareness, hand dynamometer to assess grip strength, berg balance scale to assess balance and jenkins sleep scale to assess sleep quality will be used. all tests will be measured at the start of treatment and after 4 weeks of intervention. pre- and post-intervention data were statistically analyzed and compared.

Eligibility criteria:
inclusion criteria: * being between the ages of 18-65 * being diagnosed with cervical disc herniation * being diagnosed with cervical disc herniation at the level of bulging or protrusion according to mri results exclusion criteria: * presence of cervical spine surgery history * presence of primary or spinal metastatic malignancy * having vascular problems * individuals with sleep apnea * those who use psychiatric drugs * presence of various pathologies in the upper extremity (fracture, ganglion cyst, etc.)

Keywords: graston technique cupping therapy
assessment of cognitive functioning as it relates to risk for suicide in veterans with hiv/aids

Conditions: HIV/AIDS

Summary: the purpose of this project is to gather pilot data related to exploring relationships between cognitive impairment and/or psychiatric distress and suicidal thoughts and/or behaviors in veterans with human immunodeficiency virus (hiv)/acquired immune deficiency syndrome (aids). to achieve this goal, a neuropsychological battery will be administered to veterans with hiv/aids.


Eligibility criteria:
inclusion criteria: * veterans between ages 18 to 65 * have a diagnosis of hiv/aids confirmed via medical record * currently receiving or eligible to receive physical and/or mental health care through the va eastern colorado health care system exclusion criteria: * acute intoxication via alcohol or other illicit drugs at time of assessment as determined by observation and/or interview. * psychosis at time of interview as determined by observation and/or interview. * poor test of memory malingering (tomm) performance (scores below 25 on trial 1 or scores lower than 45 on trial 2) * current status as a prisoner

Keywords: veterans hiv aids cognitive functioning suicide